
AstraZeneca continues to build on its relationship with San Diego-based Ionis Pharmaceuticals, this time by agreeing a licensing deal for …

Sailing against the prevailing winds in the Alzheimer’s disease space, AbbVie has launched a deal worth a potential $1.1 billion …

Google and Verily Life Sciences, a subsidiary within Alphabet, focused on developing health-tech, have revealed the fruits of a combined …

Apricus Biosciences had a lot riding on its application to the FDA for its erectile dysfunction cream, Vitaros, with the …

The fate of pharma company’s profits and losses largely rests on product approvals and the sales team behind them but, …

AstraZeneca’s immunotherapy, Imfinzi, arrived to the industry as a failure – there were big hopes resting on the company’s Mystic …

Another week is finished and it’s been a disastrous one for research into a potential treatment for Alzheimer’s disease. Two of …

Alzheimer’s disease (AD) is an area badly in need of a treatment, the problem is that this prospect seems to …

Biotechs are known for getting off the ground early with serious levels of financing, often based more on the acumen …

Biogen made investors very nervous after it announced that it was choosing to add an additional 510 patients to its …

Astellas Pharma had only signed an exclusive licensing deal with Universal Cells back in October for the co-development of a …

The IL-17 market is a crowded space, and one dominated by Novartis’ Cosentyx. Eli Lilly is attempting to challenge that, …

BC Platforms, a company that focuses on genomic data managements and analysis, has announced that it has partnered with Pfizer …

The Bill & Melina Gates Foundation had already invested $52 million in CureVac, back in 2015, and has now doubled …

All eyes are on Vertex’s two Phase 3 trials into a triple therapy for cystic fibrosis (CF), in the meantime, …